Strong domestic formulations, chronic therapies, new US launches and a complex-product pipeline have supported the rally, though valuations now stand above historical averages
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.